 LEXINGTON, Mass., March 03, 2021 GLOBE NEWSWIRE -- Translate Bio Nasdaq: TBIO, a clinical-stage messenger RNA mRNA therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today reported that on March 1, 2021, the Company granted non-qualified stock options to purchase an aggregate of 54,250 shares of the Companys common stock to seven newly hired employees. These grants were made pursuant to the Companys 2021 Inducement Stock Incentive Plan, were approved by the Companys Inducement Grant Subcommittee of the board of directors, and were made as a material inducement to each employees acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635c4 as a component of his or her employment compensation. 